EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Olezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome

Asia Sikora Kessler, Montserrat Vera-Llonch, Ewa Karwatowska-Prokopczuk, Veronica J Alexander, Quratul Ann, Catalina Mejia Herrera, Spyros Paparrodopoulos, Shuting Xia, Erik S G Stroes, Seth J Baum, Sotirios Tsimikas, Balance Investigators

Journal of Clinical Lipidology · 2026

DOI: 10.1016/j.jacl.2025.12.018 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Asia Sikora Kessler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Ionis, Carlsbad, CA, USA (Dr Kessler, Vera-Llonch, Dr Karwatowska-Prokopczuk, Dr Alexander, Xia, and Dr Tsimikas). Electronic address: ASikoraKessler…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type I, Patient Acceptance of Health Care, Oligonucleotides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder associated with extreme hypertriglyceridemia and high risk of acute pancreatitis. Olezarsen-an antisense oligonucleotide targeting hepatic apolipoprotein C3 (APOC3) messenger RNA-reduces triglycerides and may decrease pancreatitis risk. Olezarsen 80 mg once monthly is approved in the United States as an adjunct to diet to reduce triglycerides in adults with FCS. OBJECTIVE: To assess the effect of olezarsen on all-cause healthcare resource utilization (HCRU) and overall experience of patients with genetically identified FCS enrolled in the Balance trial (NCT04568434). METHODS: Prespecified exploratory endpoints included yearly all-cause hospitalization, total inpatient days, and emergency room visits for patients treated with olezarsen (80 or 50 mg) vs placebo, as well as Patient Global Impression of Change (PGIC). Ad hoc outcomes included length of hospital stay, intensive care unit (ICU) admissions, reasons for HCRU, and all-cause HCRU according to patients' history of acute pancreatitis and for individual olezarsen doses vs placebo. RESULTS: Treatment with olezarsen vs placebo for 1 year was associated with an 84% reduction in all-cause hospitalizations (mean rate ratio [95% CI], 0.16 [0.05, 0.50]), 6.3 fewer total inpatient days (95% CI, -11.09, -1.53), better PGIC scores, shorter length of stay, and numerically fewer ICU admissions. Acute pancreatitis was the most frequent cause of hospitalization. Reduction in all-cause inpatient service utilization was consistent for individual dose groups and in patients with a history of acute pancreatitis. CONCLUSION: In the Balance study, olezarsen reduced all-cause inpatient service utilization and improved the experience of patients with FCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IPatient Acceptance of Health CareOligonucleotidesHumansMaleFemaleMiddle AgedAdultHospitalization

Stichwörter der Autor:innen

Disease burdenEmergency room visitsFamilial chylomicronemia syndromeHealthcare resource utilizationHospitalizationsInpatient daysIntensive care unitLength of stayOlezarsenPGIC

Substanzen

Oligonucleotidesolezarsen

Autor:innen und Institutionen

  • Ionis, Carlsbad, CA, USA (Dr Kessler, Vera-Llonch, Dr Karwatowska-Prokopczuk, Dr Alexander, Xia, and Dr Tsimikas). Electronic address: ASikoraKessler@ionis.com.
  • Ionis, Carlsbad, CA, USA (Dr Kessler, Vera-Llonch, Dr Karwatowska-Prokopczuk, Dr Alexander, Xia, and Dr Tsimikas).
  • IQVIA Ltd, London, UK (Ann).
  • IQVIA Ltd, Frankfurt, Germany (Herrera).
  • IQVIA Ltd, Athens, Greece (Paparrodopoulos).
  • Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands (Dr Stroes).

Förderung

  • Ionis Pharmaceuticals

Zitieren

APA

Sikora Kessler, A., Vera-Llonch, M., Karwatowska-Prokopczuk, E., Alexander, V. J., Ann, Q., Mejia Herrera, C., Paparrodopoulos, S., Xia, S., Stroes, E. S. G., Baum, S. J., Tsimikas, S., & Balance Investigators (2026). Olezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.12.018

Vancouver

Sikora Kessler A, Vera-Llonch M, Karwatowska-Prokopczuk E, Alexander VJ, Ann Q, Mejia Herrera C, et al. Olezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2025.12.018

BibTeX
@article{SikoraKessler2026,
  author = {Sikora Kessler, Asia and Vera-Llonch, Montserrat and Karwatowska-Prokopczuk, Ewa and Alexander, Veronica J and Ann, Quratul and Mejia Herrera, Catalina and Paparrodopoulos, Spyros and Xia, Shuting and Stroes, Erik S G and Baum, Seth J and Tsimikas, Sotirios and Balance Investigators, Balance Investigators},
  title = {Olezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  doi = {10.1016/j.jacl.2025.12.018}
}
Kostenlos starten →